OKYO Pharma releases promising data on dry-eye candidate

UK-headquartered clinical-stage company OKYO Pharma’s (Nasdaq: OKYO) today shared promising new categorical data analyses from the recent OK-101 Phase II trial in dry eye disease (DED) patients.

These analyses have identified conjunctival staining and ocular pain as the highest potential “sign” and “symptom” co-primary endpoints to be explored in the next DED trial of OK-101, said the company, whose share rose 5% in pre-market activity but were down 3.4% at $1.15 by mid-morning.

OKYO pointed out that the key findings of the study were: